Abiopharma

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

XWELL Reaffirms Commitment to Biosecurity, Appoints Former CDC Senior Advisor

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Collegium Provides 2026 Financial Guidance and Business Update

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

New Form SCHEDULE 13G - JOINT Corp Filed: 2026-01-08 AccNo: 0001821268-26-000003 Size: 6 KB

Curaleaf Announces Proposed Domestication to Delaware

(90% Positive) Context Therapeutics Inc. (CNTX) Provides Update on reflected for such are reasonable

New Form ARS - Modular Medical, Inc. Filed: 2026-01-08 AccNo: 0001213900-26-002333 Size: 731 KB

New Form DEF 14A - Modular Medical, Inc. Filed: 2026-01-08 AccNo: 0001213900-26-002332 Size: 22 MB

GH Research PLC (GHRS) Files Form 6-K

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases